United Therapeutics
$571.38Change from previous close: +5.44%Absolute change: +$29.49
Valuation
Data as of October 2, 2026
Valuation multiples
- Market cap
- $24.51B
- Enterprise value
- $21.84B
- P/E (trailing 12 months)
- 20.5
- Forward P/E
- 19.0
- PEG
- 2.22
- Price/book
- 3.81
- Price/sales
- 7.77
- EV/EBITDA
- 14.6
- EV/revenue
- 6.93
Profitability and growth
- Gross margin
- 86.1%
- Operating margin
- 42.2%
- Net margin
- 41.6%
- ROE
- 19.3%
- ROA
- 11.6%
- Revenue growth (year over year)
- -1.9%
- Earnings growth (year over year)
- 13.4%
Financial health
- Total cash
- $2.66B
- Total debt
- $0
- Current ratio
- 5.73
- Quick ratio
- 4.89
Dividends
- Payout ratio
- 0.0%
Analysts and estimates
- Average price target
- $644.36
- Median price target
- $685.00
- High price target
- $728.00
- Low price target
- $321.00
- Analysts with a price target
- 14
- Consensus
- Buy
- Forward EPS
- $30.03
- EPS estimate, current year
- $26.08
Shares and trading
- Beta
- 0.56
- Average volume
- 600.07K
- Shares outstanding
- 42.89M
- Float
- 39.21M
- Institutional ownership
- 99.9%
- Insider ownership
- 2.0%
- Short interest (% of float)
- 7.6%
- Short ratio (days)
- 4.89